Last reviewed · How we verify
NCT03872141
Objective Evaluation of Paclitaxel/Docetaxel-induced Neuropathy in Breast Cancer Patients
trial testing Quantitative measures of reduction in Chemotherapy Induced Neuropathy (CIPN) and Cognitive Impairment (CICI) in patients with stage I-III breast cancer in Breast Cancer in 13 participants. Completed in 25 February 2021.
25 February 2021
Quick facts
| Lead sponsor | Yale University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 13 |
| Start date | 23 May 2017 |
| Primary completion | 25 February 2021 |
| Estimated completion | 25 February 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Quantitative measures of reduction in Chemotherapy Induced Neuropathy (CIPN) and Cognitive Impairment (CICI) in patients with stage I-III breast cancer
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Chemotherapy Induced Peripheral Neuropathy — all drugs for Chemotherapy Induced Peripheral Neuropathy →
- Paclitaxel Induced Neuropathy — all drugs for Paclitaxel Induced Neuropathy →
Sponsor
Yale University
Who can join
Adults 18 to 70, female only, with Breast Cancer or Chemotherapy Induced Peripheral Neuropathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this prospective, non-interventional study is to perform neurological and cognitive assessment of breast cancer patients who receive standard of care single agent weekly paclitaxel docetaxel chemotherapy to determine the onset and severity of chemotherapy induced neuropathy (CIPN) and cognitive impairment (CICI).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy.
Ibrahim EY, Munshani S, Domenicano I, Rodwin R, et al · · 2022 · cited 11× · PMID 36206298 · DOI 10.1371/journal.pone.0275648
Verify or expand the search:
- PubMed search for NCT03872141
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Yale University trials
Trials by the same sponsor.
- NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
- NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
- NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
- NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
- NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03872141 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yale University
- Last refreshed: 3 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03872141.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing